CRISPR trials yield encouraging data in blood disorders

Vertex gets early okay for cystic fibrosis triple Trikafta i...

Labour government would use compulsory licensing for expensi...

Vertex’ chief Leiden to step down, with CMO named successor

Vertex presses go on its cystic fibrosis triple filing

R&D roundup: the ups and downs of CRISPR and Alzheimer’s

While the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm has announced that it is licensing back two gene editing compounds that can